| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | FMOD |
| Uniprot No | Q06828 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-376aa |
| 氨基酸序列 | MQWTSLLLLAGLFSLSQAQYEDDPHWWFHYLRSQQSTYYDPYDPYPYETYEPYPYGVDEGPAYTYGSPSPPDPRDCPQECDCPPNFPTAMYCDNRNLKYLPFVPSRMKYVYFQNNQITSIQEGVFDNATGLLWIALHGNQITSDKVGRKVFSKLRHLERLYLDHNNLTRMPGPLPRSLRELHLDHNQISRVPNNALEGLENLTALYLQHNEIQEVGSSMRGLRSLILLDLSYNHLRKVPDGLPSALEQLYMEHNNVYTVPDSYFRGAPKLLYVRLSHNSLTNNGLASNTFNSSSLLELDLSYNQLQKIPPVNTNLENLYLQGNRINEFSISSFCTVVDVVNFSKLQVLRLDGNEIKRSAMPADAPLCLRLASLIEI |
| 预测分子量 | 43,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与FMOD(Fibromodulin)重组蛋白相关的代表性文献摘要示例：
---
1. **文献名称**：*Recombinant Fibromodulin Enhances Cartilage Repair by Modulating Collagen Fibrillogenesis*
**作者**：Häusler G, et al.
**摘要**：研究证明重组FMOD蛋白通过调控Ⅱ型胶原纤维的组装，促进软骨细胞外基质的形成，显著改善动物模型中的软骨损伤修复，提示其在关节组织工程中的应用潜力。
---
2. **文献名称**：*Fibromodulin Reduces Scar Formation in Cutaneous Wound Healing*
**作者**：Tao J, et al.
**摘要**：该文献发现重组FMOD通过抑制TGF-β/Smad3信号通路，减少肌成纤维细胞分化，从而降低皮肤伤口愈合过程中的纤维化，为无瘢痕修复提供新策略。
---
3. **文献名称**：*FMOD and VEGF Synergistically Promote Bone Regeneration*
**作者**：Jiang Y, et al.
**摘要**：研究显示重组FMOD与血管内皮生长因子(VEGF)协同作用，通过激活整合素信号通路，同时促进血管生成和成骨分化，显著加速骨缺损模型中的再生过程。
---
4. **文献名称**：*Recombinant Fibromodulin Modulates Stem Cell Differentiation for Tendon Repair*
**作者**：Wang L, et al.
**摘要**：实验表明，重组FMOD通过调控细胞外基质的力学特性，诱导间充质干细胞向肌腱细胞分化，并增强肌腱损伤后的生物力学性能，为肌腱再生提供新方法。
---
**注**：以上文献信息为示例性概括，实际引用需根据具体研究核实作者、标题及内容。建议通过PubMed或Web of Science以“recombinant Fibromodulin”为关键词检索最新文献。
FMOD (fibromodulin) is a small leucine-rich repeat proteoglycan (SLRP) primarily found in the extracellular matrix (ECM) of connective tissues. It plays a critical role in regulating collagen fibrillogenesis, influencing tissue organization, and modulating cell signaling pathways. FMOD interacts with collagen fibrils to control their diameter and spacing, contributing to the structural integrity of tissues like cartilage, tendons, and skin. Beyond its structural functions, FMOD exhibits bioactive properties, including anti-inflammatory and anti-fibrotic effects, by interacting with growth factors such as TGF-β and modulating immune responses.
Recombinant FMOD (rFMOD) is produced using genetic engineering techniques, often expressed in mammalian or bacterial systems to ensure proper post-translational modifications. This engineered protein retains the functional domains of native FMOD, enabling its use in biomedical research and therapeutic development. Studies highlight its potential in tissue regeneration, particularly in wound healing and osteoarthritis treatment, where it promotes ECM remodeling and reduces scar formation. Its ability to enhance stem cell differentiation and tissue repair has drawn interest in regenerative medicine.
Recent research also explores rFMOD’s role in mitigating fibrosis in organs like the liver and lungs by suppressing excessive collagen deposition. Additionally, its anti-angiogenic properties are being investigated for cancer therapy. Despite promising preclinical results, challenges remain in optimizing delivery methods and understanding long-term safety profiles. Collaborations between academia and biotech firms aim to advance rFMOD toward clinical trials, positioning it as a versatile candidate for addressing ECM-related disorders and improving regenerative therapies.
×
